Insight Molecular Diagnostics Files 8-K
Ticker: IMDX · Form: 8-K · Filed: Aug 11, 2025 · CIK: 1642380
Sentiment: neutral
Topics: financial-reporting, operations, company-update
TL;DR
Insight Molecular Diagnostics filed an 8-K on Aug 11, 2025, updating financials.
AI Summary
Insight Molecular Diagnostics Inc. filed an 8-K on August 11, 2025, reporting on its Results of Operations and Financial Condition. The filing also includes Financial Statements and Exhibits. The company, formerly known as Oncocyte Corp, is incorporated in California and based in Nashville, Tennessee.
Why It Matters
This 8-K filing provides an update on the company's financial condition and operations, which is crucial for investors to assess its current performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Insight Molecular Diagnostics Inc. (company) — Registrant
- Oncocyte Corp (company) — Former company name
- August 11, 2025 (date) — Filing date
- Nashville, Tennessee (location) — Company address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Insight Molecular Diagnostics Inc., and to include Financial Statements and Exhibits.
When was this 8-K filed?
This 8-K was filed on August 11, 2025.
What was Insight Molecular Diagnostics Inc. previously known as?
Insight Molecular Diagnostics Inc. was formerly known as Oncocyte Corp.
Where is Insight Molecular Diagnostics Inc. located?
Insight Molecular Diagnostics Inc. is located at 2 International Plaza Dr., Suite 510, Nashville, Tennessee 37217.
What is the company's state of incorporation?
The company's state of incorporation is California.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-08-11 16:10:16
Filing Documents
- form8-k.htm (8-K) — 35KB
- ex99-1.htm (EX-99.1) — 387KB
- ex99-1_001.jpg (GRAPHIC) — 53KB
- 0001641172-25-022974.txt ( ) — 686KB
- imdx-20250811.xsd (EX-101.SCH) — 3KB
- imdx-20250811_lab.xml (EX-101.LAB) — 33KB
- imdx-20250811_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INSIGHT MOLECULAR DIAGNOSTICS INC. Date: August 11, 2025 By: /s/ Peter Hong Name: Peter Hong Title: Vice President, General Counsel